Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Amgen (NASDAQ:AMGN – Free Report) had its price objective raised by Bank of America from $275.00 to $294.00 in a report released on Wednesday morning,Benzinga reports. Bank of America currently has an ...

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

This week's dividend activity included increased payouts from Bestbuy (BBY) and JD.com (NASDAQ:JD) as well as declarations ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...